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Abstract
Aims To assess the risk of adverse neonatal outcomes in women with gestational diabetes (GDM) by identifying subgroups 
of women at higher risk to recognize the characteristics most associated with an excess of risk.
Methods Observational, retrospective, multicenter study involving consecutive women with GDM. To identify distinct and 
homogeneous subgroups of women at a higher risk, the RECursive Partitioning and AMalgamation (RECPAM) method 
was used. Overall, 2736 pregnancies complicated by GDM were analyzed. The main outcome measure was the occurrence 
of adverse neonatal outcomes in pregnancies complicated by GDM.
Results Among study participants (median age 36.8 years, pre-gestational BMI 24.8 kg/m2), six miscarriages, one neonatal 
death, but no maternal death was recorded. The occurrence of the cumulative adverse outcome (OR 2.48, 95% CI 1.59–3.87), 
large for gestational age (OR 3.99, 95% CI 2.40–6.63), fetal malformation (OR 2.66, 95% CI 1.00–7.18), and respiratory 
distress (OR 4.33, 95% CI 1.33–14.12) was associated with previous macrosomia. Large for gestational age was also associ-
ated with obesity (OR 1.46, 95% CI 1.00–2.15). Small for gestational age was associated with first trimester glucose levels 
(OR 1.96, 95% CI 1.04–3.69). Neonatal hypoglycemia was associated with overweight (OR 1.52, 95% CI 1.02–2.27) and 
obesity (OR 1.62, 95% CI 1.04–2.51). The RECPAM analysis identified high-risk subgroups mainly characterized by high 
pre-pregnancy BMI (OR 1.68, 95% CI 1.21–2.33 for obese; OR 1.38 95% CI 1.03–1.87 for overweight).
Conclusions A deep investigation on the factors associated with adverse neonatal outcomes requires a risk stratification. In 
particular, great attention must be paid to the prevention and treatment of obesity.
Keywords Gestational diabetes · Neonatal outcomes · Risk stratification · Obesity
Introduction
Gestational diabetes mellitus (GDM) is defined as an altera-
tion in blood glucose that occurs or is first identified in preg-
nancy [1]. Its development is primarily caused by the effect 
of pregnancy hormonal status. Recently, also a role of gut 
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microbiota composition was hypothesized, gut microbiota 
aberrations preceding the diagnosis of GDM [2]. Despite 
the divergence at international level about the most appropri-
ate screening and diagnostic procedures, its prevalence until 
2010 was between 2–9% [3, 4], being about 7% in Italy [5]. 
GDM represents a pathological condition for the mother and 
the fetus during pregnancy, at delivery and in the follow-up 
period. Women with GDM have an increased risk of adverse 
obstetric events and adverse neonatal outcomes compared 
to women with physiological pregnancy [6]. In particular, 
GDM is associated with a greater risk of fetal macrosomia, 
shoulder dystocia, neonatal trauma, neonatal jaundice, res-
piratory distress, and neonatal hypoglycemia [7–10]. In 
addition, children of mothers with GDM could need more 
neonatal intensive care [11]. Recent evidence underlines the 
importance of early identification of GDM and its subse-
quent treatment to promote maternal–fetal health [12–14]. 
Two major randomized studies have shown that reducing 
maternal blood glucose levels was associated with a reduc-
tion in the occurrence of adverse outcomes [12, 13]. GDM 
is also associated with an increased risk of cardiovascular 
disease [15] and type 2 diabetes development [16, 17] after 
delivery compared to normal pregnancy. A systematic mul-
tidisciplinary management of pregnant women in the diag-
nosis and treatment of GDM is essential to contain these 
maternal and fetal complications [18].
Based on the HAPO (Hyperglycemia and Adverse Preg-
nancy Outcomes) study [19], a panel of international experts 
(IADPSG) has defined new guidelines for screening and 
diagnosis of GDM [20]. They consisted in the modification 
of the previous threshold glucose values of the diagnostic 
oral glucose tolerance test (OGTT) and the reduction in the 
number of altered OGTT points (from 2 to only 1) required 
to formulate the diagnosis. This led to an increase in the fre-
quency of GDM. Another important change of the IADPSG 
guidelines is that now a universal one-step approach is rec-
ommended with a 75 g OGTT instead of selective screening 
based on risk factors or screening in a two-step approach 
with a glucose challenge test.
The new diagnostic criteria implies significant practical 
consequences in terms of care. Many of the situations pre-
viously classified as minor glucose alterations of the preg-
nancy, usually addressed by a less aggressive management 
approach, are now included into a single category labeled as 
GDM. This has a high impact on the caseload of specialist 
centers and, overall, on healthcare costs. In Italy, the most 
recent estimates of GDM prevalence diagnosed according to 
Italian criteria are around 11% [21].
However, GDM intensity of care pathway may be mod-
ulated on the basis of GDM severity defined not only as 
a degree of glucose impairment, but as an overall risk of 
adverse neonatal outcomes. Recognizing specific subgroups 
of women at high of risk adverse neonatal outcomes would 
help to align therapeutic attitudes toward more or less inten-
sity and timeliness to ensure maternal–fetal–neonatal well-
being and to maximize the appropriateness of use of avail-
able resources.
Aim of our study was to assess the risk of adverse neo-
natal outcomes in women with gestational diabetes and to 
identify subgroups of women at a high risk for adverse neo-
natal outcome.
Methods
The study had an observational, retrospective, multicentre 
design. It involved women with pregnancy complicated by 
GDM cared for by Italian diabetes Centers between Janu-
ary 2012 and May 2015. All the centers with a specialized 
outpatient clinic dedicated to GDM care have been involved. 
To have representative data of the centers normally caring 
for women with GDM only those with more than 30 cases 
of GDM per year during the study period were involved. 
Women were universally screened early in pregnancy (in 
the first trimester) to exclude overt diabetes. The diagnosis 
of GDM, according to current Italian recommendations, was 
considered whether it was confirmed at 16–18th or at the 
24–28th weeks of gestation [22]. Screening for GDM is rec-
ommended for women with physiological pregnancy, using 
defined risk factors. In particular, it is recommended that 
women with at least one of the following conditions should 
be screened at 16–18 weeks of gestation: previous GDM, 
pre-pregnancy body mass index (BMI) ≥ 30 kg/m2, plasma 
glucose values at the beginning of pregnancy (within the 
first trimester) between 100 and 125 mg/dl (5.6–6.9 mmol/l). 
An oral glucose tolerance test with 75 g of glucose (OGTT-
75 g) should be offered to these women. In case of normal 
OGTT results the test should be repeated at 24–28 weeks 
of gestation. The risk factors considered at 24–28 weeks of 
gestation are: age ≥ 35 years, pre-pregnancy BMI ≥ 25 kg/
m2, fetal macrosomia in a previous pregnancy (≥ 4.5 kg), 
family history of diabetes (first-degree relative with type 
2 diabetes), family origin from areas at high prevalence of 
diabetes. Women with one or more plasma glucose values 
above the established thresholds (≥ 92 mg/dl at baseline, 
≥ 180 mg/dl after 1 h from the load, ≥ 153 mg/dl after 2 h 
from the load) are defined as having GDM.
After the diagnosis, women with GDM are invited to 
perform self-monitoring blood glucose measurement (fast-
ing and 1 h after meal with glycemic targets of < 95 and 
< 130 mg/dl, respectively), to follow a balanced diet (total 
kcal calculated according to pre-gestational BMI), and to 
do regular physical activity. If blood glucose is not in tar-
get a pharmacological therapy (in Italy the only possible is 
insulin) is started.
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Women with the following characteristics were eligible 
for this study: age ≥ 18 years, delivery by May 2015, signa-
ture of informed consent. Exclusion criteria were: diagnosis 
of pre-gestational diabetes, twin pregnancy. The following 
data of the studied women were collected: socio-demo-
graphic characteristics, risk factors for GDM, laboratory 
parameters, therapy, fetal ultrasound parameters, ketones 
testing (yes/no), average number of weekly self-monitoring 
of blood glucose tests, number of diabetes visits from GDM 
diagnosis to delivery, follow-up visit after delivery.
Information on maternal–fetal outcomes such as ade-
quate, large or small fetal growth for gestational age, mac-
rosomia, minor and major malformations, neonatal intensive 
care need, neonatal hypoglycemia needing i.v. treatment, 
neonatal hypocalcemia, neonatal hyperbilirubinemia, shoul-
der distocia, respiratory distress, type of delivery, stillbirths, 
maternal mortality, neonatal mortality, child weight, and 
length at birth was also collected.
Outcomes definition
The variable neonatal adverse outcome was defined as the 
presence of one or more of the following adverse neonatal 
outcomes: fetal growth large or small for gestational age, 
mortality, malformations, shoulder distocia, neonatal inten-
sive care need, hypoglycaemia, hypocalcemia, hyperbiliru-
binemia, and respiratory distress.
Newborns were considered large for gestational age 
(LGA) if birth weight was greater than 90th percentile and 
small for gestational age (SGA) if birth weight was less than 
10th percentile, based on national anthropometric standards 
adapted for sex and parity. Macrosomia was defined as a 
delivery weight greater than 4000 g. Neonatal hypoglycae-
mia was defined as blood glucose less than 40 mg/dl dur-
ing the first 24 h of life. Hyperbilirubinemia was defined 
as blood bilirubin greater than 12 mg/dl. Respiratory dis-
tress was defined as respiratory insufficiency, presenting as 
changes in respiratory frequency, apnoeic spells, bradycardia 
and cyanosis. Malformations were classified according to 
EUROCAT. Shoulder distocia was defined as a damage of 
the shoulder of a newly delivered child, often as a result of 
physical pressure or trauma during childbirth.
All information was collected on an electronic data col-
lection platform. To ensure anonymity, all patients have been 
identified by a unique code. Only the responsible doctor of 
the center and the authorized subjects were able to link this 
code to the corresponding patient.
The study was conducted in accordance with the Helsinki 
Declaration on Medical Research on Humans and with the 
Good Clinical Practice (GCP). The study was approved by 
the Ethics Committees of all participating Centers. Partici-
pant patients gave informed consent before taking part.
Statistical analysis
Sample size estimation was based on the most prevalent 
maternal–fetal outcome that was represented by large for 
gestational age (LGA). From Italian literature a prevalence 
of LGA of approximately 19.6% [13] for women with GDM 
was considered. To identify with a statistical power 80% 
(α = 0.05) risk factors with a minimum prevalence of 15% 
in the study population and associated with an odds ratio 
(OR) ≥ 1.7, enrollment of at least 1000 women with GDM 
was required.
Descriptive data were summarized as mean and standard 
deviation, median and interquartile ranges, or percentages, 
depending on the type of variables. The characteristics of the 
study population were categorized based on the presence or 
absence of unfavorable neonatal outcomes and were com-
pared using Student’s test (continuous variables normally 
distributed), Mann–Whitney test (continuous variables not 
normally distributed), or the chi-square test (categorical 
variables). Logistic regression models were used to evaluate 
the factors most associated with neonatal adverse outcomes. 
Dependent variables of the single logistic models were the 
same components of the cumulative neonatal outcome. The 
same set of covariates was tested in each model: age, pre-
pregnancy BMI, previous GDM, family history of diabetes, 
area of family origin, previous macrosomia, and plasma glu-
cose values at the beginning of pregnancy between 100 and 
125 mg/dl (5.6–6.9 mmol/l). Separate multivariate analyses 
including also OGTT glucose levels at 16–18 gestational 
weeks or at 24–28 gestational weeks were performed. In 
addition, to identify distinct and homogeneous subgroups 
of patients at a higher risk of developing adverse neonatal 
outcomes, the RECursive Partitioning and AMalgamation 
(RECPAM) [23–25] method was used. This method chooses 
the covariate and its best binary split to maximize the risk 
difference of having adverse neonatal outcomes. In the REC-
PAM model, both categorical and continuous variables have 
been tested to allow the algorithm to choose the natural cut-
off point. A p value < 0.05 was considered statistically sig-
nificant. All analyses were performed using the SAS version 
9.3 (SAS Institute Inc.) program.
Results
Overall, 2736 pregnancies were analyzed. General character-
istics of the studied population and information on neonatal 
outcomes are reported in Table 1.
Six stillbirths, one neonatal death but no maternal 
death was recorded. Features of participants according to 
the presence of adverse neonatal outcomes are reported in 
Table 2. Women with adverse neonatal outcomes (29.8%) 
had higher pre-gestational BMI, HbA1c levels at diagnosis, 
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Table 1  General clinical 
characteristics of the studied 
population
N 2736
Age (years) 36.6 ± 5.1
Age classes (%)
 ≤ 35 years 37.2
 > 35 years 62.8
Education (%)
 Low 26.0
 Median 48.7
 High 25.3
Occupation (%)
 Housewife 35.3
 Employed 64.0
 Student 0.7
Physical activity before pregnancy (%) 25.2
Physical activity during pregnancy (%) 25.9
Alcohol before pregnancy (%) 7.6
Alcohol during pregnancy (%) 2.6
Smoke (%)
 No 78.5
 Yes 9.5
 Ex 12.0
Race Caucasian (%) 44.8
Family from areas of high diabetes prevalence (%) 9.4
Family history of diabetes (%) 41.7
First pregnancy (%) 45.3
Number of previous pregnancy (n) 1.0 (1.0–2.0)
Previous abortion (%) 26.6
Number of previous abortion (n) 0.0 (0.0–1.0)
Previous GDM (%) 14.1
Previous macrosomia (%) 3.5
Weight before pregnancy (kg) 68.6 ± 15.7
Height (cm) 162.4 ± 6.7
Pre-pregnancy BMI (kg/m2) 24.8 (21.9–28.9)
Pre-pregnancy BMI classes (%)
 < 25 kg/m2 51.7
 25–30 kg/m2 27.7
 > 30 kg/m2 20.5
Weight at OGTT (kg) 75.4 ± 15.0
Weight at end of pregnancy (kg) 78.8 ± 15.1
Weight gain (kg) 9.9 ± 5.7
Blood glucose at first trimester (mg/dl) 88.8 ± 11.6
First trimester blood glucose between 100 and 125 mg/dl (%) 24.5
HbA1c at diagnosis % (mmol/mol) 5.1 ± 0.8 (32.7 ± 8.4)
16–18 weeks OGTT blood glucose T0′ (mg/dl) 94.7 ± 10.0
16–18 weeks OGTT Blood glucose T60′ (mg/dl) 163.9 ± 35.8
16–18 weeks OGTT blood glucose T120′ (mg/dl) 136.1 ± 33.8
24–28 weeks OGTT blood glucose T0′ (mg/dl) 86.2 ± 21.3
24–28 weeks OGTT blood glucose T60′ (mg/dl) 175.9 ± 31.4
24–28 weeks OGTT blood glucose T120′ (mg/dl) 147.2 ± 31.6
Systolic blood pressure (mmHg) 112.2 ± 13.5
Diastolic blood pressure (mmHg) 70.4 ± 9.7
Total cholesterol (mg/dl) 250.0 (217.0–280.0)
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OGTT basal glucose levels at 16–18 gestational weeks, 
previous macrosomia rate, number of previous abortion, 
and diastolic blood pressure levels, consumed more alco-
hol before pregnancy, more often were not Caucasian, and 
delivered at an earlier gestational week when compared 
with women without adverse outcomes. The occurrence 
of the adverse outcomes was only associated with previ-
ous macrosomia (OR 2.48, 95% CI 1.59–3.87). LGA (OR 
3.99, 95% CI 2.40–6.63), fetal malformation (OR 2.66, 95% 
CI 1.00–7.18), and respiratory distress (OR 4.33, 95% CI 
1.33–14.12) were also associated with previous macrosomia. 
LGA was also associated with obesity (OR 1.46, 95% CI 
1.00–2.15). Small for gestational age was associated with 
first trimester glucose levels (OR 1.96, 95% CI 1.04–3.69). 
Neonatal hypoglycemia was associated with overweight 
(OR 1.52, 95% CI 1.02–2.27) and obesity (OR 1.62, 95% CI 
1.04–2.51). No significant predictors were found when oth-
ers multivariate analyses were performed considering neo-
natal intensive care, hypocalcemia, or hyperbilirubinemia as 
dependent variable. Separate multivariate analyses including 
also OGTT glucose levels at 16–18 gestational weeks or at 
24–28 gestational weeks did not show any predictive role 
Table 1  (continued) HDL cholesterol (mg/dl) 68.0 (57.0–79.0)
LDL cholesterol (mg/dl) 139.0 (112.0–165.6)
Triglycerides (mg/dl) 192.0 (146.0–248.0)
Gestational week at first visit (weeks) 28.0 (24.0–30.0)
Number of diabetes visits (n) 4.0 (3.0–6.0)
Number of weekly SMBG tests (n) 21.0 (14.0–28.0)
Ketones measurement (%) 55.7
Glucose lowering treatment (%)
 Diet 58.7
 Insulin 41.3
Insulin treatment started during the first visit (%) 12.5
Anti-ipertensive treatment (%) 5.0
Antiplatelet treatment (%) 6.2
Levotiroxina treatment (%) 13.3
Other treatments (%) 27.7
Women attending the follow-up visit (%) 46.2
Follow-up OGTT T0′ (mg/dl) 91.0 ± 10.7
Follow-up OGTT T120′ (mg/dl) 101.9 ± 28.7
Pregnancy and neonatal outcomes
 Gestational week at delivery (weeks) 39.0 (38.0–40.0)
 Gender of the newborn (%)
  Female 47.3
  Male 52.7
 Weight at birth (g) 3233.2 ± 492.7
 Length at birth (cm) 49.7 ± 3.9
 Stillbirths (%) 0.3
 Mother death (n) 0
Neonatal death (n) 1
 Composite outcome (%) 29.8
 Macrosomia (> 4000 g) 4.8
 Large for gestational age (%) 9.6
 Small for gestational age (%) 5.9
 Respiratory distress (%) 3.9
 Jaundice (%) 10.4
 Neonatal hypocalcemia (%) 0.7
 Neonatal hypoglycemia (%) 7.2
 Malformation (%) 3.4
 Cesarean section (%) 46.4
 Neonatal intensive care unit need (%) 4.9
 Shoulder distocia (%) 0
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Table 2  Characteristics according to the presence of the adverse neonatal outcomes
Adverse neonatal outcomes—no Adverse neonatal out-
comes—yes
p
Age (years) 36.7 ± 5.0 36.5 ± 5.2 0.66
Age classes (%) 0.77
 ≤ 35 years 36.9 37.7
 > 35 years 63.1 62.3
Education (%) 0.02
 Low 24.3 28.3
 Median 51.3 43.3
 High 24.4 28.3
Occupation (%) 0.86
 Housewife 34.6 35.1
 Employed 64.7 64.0
 Student 0.7 1.0
Phisycal activity before pregnancy (%) 26.3 24.2 0.38
Phisycal activity during pregnancy (%) 26.2 26.6 0.85
Alcohol before pregnancy (%) 6.4 10.2 0.004
Alcohol during pregnancy (%) 26.2 26.6 0.85
Smoke (%) 0.51
 No 79.1 78.5
 Yes 9.8 8.9
 Ex 11.1 12.6
Race Caucasian (%) 48.7 43.3 0.01
Family from areas of high diabetes prevalence (%) 9.1 10.0 0.52
Family history of diabetes (%) 40.1 43.4 0.12
First pregnancy (%) 44.6 44.5 0.99
Number of previous pregnancy (n) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.20
Previous abortion (%) 26.4 26.9 0.80
Number of previous abortion (n) 0.0 (0.0–1.0) 1.0 (0.0–1.0) 0.02
Previous GDM (%) 13.8 15.9 0.19
Previous macrosomia (%) 2.3 6.2 < 0.0001
Weight before pregnancy (kg) 67.9 ± 15.2 70.0 ± 16.3 0.003
Height (cm) 162.2 ± 6.5 162.6 ± 6.8 0.29
Pre-pregnancy BMI (kg/m2) 24.4 (21.7–28.6) 25.3 (22.3–29.4) 0.003
Pre-pregnancy BMI classes (%) 0.04
 < 25 kg/m2 53.5 47.9
 25–30 kg/m2 27.7 29.9
 > 30 kg/m2 18.9 22.2
Weight at OGTT (kg) 74.7 ± 14.4 77.1 ± 16.4 0.01
Weight at end of pregnancy (kg) 78.1 ± 14.5 80.3 ± 16.1 0.008
Weight gain (kg) 9.9 ± 5.5 9.7 ± 5.7 0.56
Blood glucose at first trimester (mg/dl) 88.5 ± 10.9 89.7 ± 12.7 0.14
First trimester blood glucose between 100 and 125 mg/dl (%) 26.1 23.8 0.23
HbA1c at diagnosis % (mmol/mol) 5.2 ± 0.8 (32.2 ± 8.7) 5.1 ± 0.8 (33.8 ± 8.2) 0.001
16–18 weeks OGTT Blood glucose T0′ (mg/dl) 94.3 ± 10.0 97.1 ± 9.2 0.02
16–18 weeks OGTT Blood glucose T60′ (mg/dl) 165.1 ± 35.9 161.5 ± 37.6 0.59
16–18 weeks OGTT Blood glucose T120′ (mg/dl) 135.3 ± 33.3 137.9 ± 34.7 0.43
24–28 weeks OGTT Blood glucose T0′ (mg/dl) 86.0 ± 21.8 86.3 ± 22.2 0.78
24–28 weeks OGTT Blood glucose T60′ (mg/dl) 175.3 ± 32.1 175.9 ± 30.1 0.80
24–28 weeks OGTT Blood glucose T120′ (mg/dl) 146.0 ± 31.9 148.5 ± 31.8 0.10
Systolic blood pressure (mmHg) 111.7 ± 13.4 113.3 ± 13.9 0.008
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for OGTT glucose levels for none of the single nor for the 
cumulative neonatal adverse outcome.
RECPAM analysis
The RECPAM analysis led to the identification of four 
classes at different risks of having an adverse neonatal out-
come (Fig. 1). The reference category was represented by the 
subgroup of women with the lowest prevalence of adverse 
neonatal outcome. Thus, the ORs for all the other subgroups 
were estimated with respect to the reference class. The most 
important variable for differentiating the risk of adverse neo-
natal outcome was represented by pre-pregnancy BMI, with 
patients with pre-pregnancy BMI levels lower than 25 kg/m2 
having the lowest prevalence. Therefore, this group served 
as the reference category. On the opposite side of the regres-
sion tree, patients with a pre-pregnancy BMI > 30 kg/m2 rep-
resented the subgroup with the highest risk of the adverse 
neonatal outcome (OR 1.68, 95% CI 1.21–2.33). Women 
with pre-pregnancy BMI levels between 25 and 30 kg/m2 
(class 2) also had a significant risk of adverse neonatal out-
come compared with the reference category (OR 1.38 95% 
CI 1.03–1.87). Among women with pre-pregnancy BMI 
lower than 25 kg/m2 the stratification model built a class on 
the basis of the presence of family history for type 2 diabe-
tes but this class was not capable of further differentiating 
the risk for adverse neonatal outcomes (OR 1.17, 95% CI 
0.84–1.65). Other factors that were considered in the model 
did not contribute to the identification of distinct subgroups 
at an increased risk of adverse neonatal outcomes.
When examining the clinical characteristics of the REC-
PAM classes (Table 3), women with the highest risk had the 
highest systolic and diastolic blood pressure levels, first tri-
mester glucose values, first trimester blood glucose between 
100 and 125 mg/dl rate, HbA1c levels at GDM diagnosis, 
fasting OGTT glucose levels both at 16–18 gestational 
weeks and at 24–28 gestational weeks, insulin treatment 
rate, and more often were Caucasian. All these differences 
between RECPAM classes were statistically significant and 
a between classes trend was clearly detectable.
Discussion
Principal findings
Our study showed that the occurrence of several adverse 
neonatal outcomes was associated with specific maternal 
antenatal characteristics. In particular, a strong role of previ-
ous macrosomia and pre-pregnancy BMI levels was recog-
nized. Having a macrosomic baby in a previous pregnancy 
was associated with high risk of babies LGA, fetal malfor-
mation, respiratory distress, and a cumulative adverse neo-
natal outcome. Pre-pregnancy obesity was an independent 
Table 2  (continued)
Adverse neonatal outcomes—no Adverse neonatal out-
comes—yes
p
Diastolic blood pressure (mmHg) 70.1 ± 9.6 70.9 ± 10.0 0.04
Total cholesterol (mg/dl) 250.0 (218.0–280.0) 246.0 (216.0–282.0) 0.67
HDL cholesterol (mg/dl) 68.0 (58.0–79.0) 67.0 (56.0–80.0) 0.55
LDL cholesterol (mg/dl) 144.0 (116.0–170.0) 135.0 (111.0–165.6) 0.16
Triglycerides (mg/dl) 191.0 (142.0–242.0) 182.0 (153.0–249.0) 0.51
Gestational week at first visit (weeks) 28.0 (25.0–30.0) 28.0 (24.0–30.0) 0.96
Number of weekly SMBG tests (n) 21.0 (14.0–28.0) 21.0 (14.0–28.0) 0.40
Ketones measurement (%) 54.0 59.8 0.01
Glucose lowering treatment (%) 0.60
 Diet 60.1 59.0
 Insulin 39.9 41.0
Insulin treatment started during the first visit (%) 11.0 14.0 0.14
Follow-up OGTT T0′ (mg/dl) 90.1 ± 9.8 93.3 ± 12.4 0.001
Follow-up OGTT T120′ (mg/dl) 101.1 ± 28.0 103.8 ± 30.2 0.22
Gestational week at delivery (weeks) 39.0 (38.0–40.0) 38.0 (37.0–39.0) < 0.0001
Weight at birth (g) 3237.5 ± 384.2 3224.6 ± 662.1 0.99
Lenght at birth (cm) 49.9 ± 4.2 49.4 ± 3.1 0.19
Gender of the newborn (%) 0.08
 Female 48.7 44.6
 Male 51.3 55.4
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risk factor for LGA and neonatal hypoglycemia. The role of 
pre-pregnancy BMI levels was further highlighted by the 
regression tree analysis we have performed. It identified 
obese women as the subgroup with the highest prevalence of 
adverse neonatal outcome. These high-risk women had also 
the highest systolic and diastolic blood pressure levels, first 
trimester glucose values, HbA1c levels at GDM diagnosis, 
and more often were not Caucasian. Furthermore, they more 
often required an insulin treatment to keep their glucose lev-
els in target. Overweight women were also at higher risk of 
adverse neonatal outcome when compared with women with 
normal BMI. As obesity is known to negatively impact on 
maternal and neonatal course during pregnancy, it is impor-
tant to highlight that also in a large Italian cohort this finding 
is confirmed.
Finally, our study did not show any predictive role of 
OGTT glucose levels with respect to the occurrence of 
adverse neonatal outcomes.
Comparison with existing knowledge
The STRONG study is the largest Italian multicenter study 
on GDM outcomes since new diagnostic criteria for GDM 
were approved. Other studies focused on this topic were per-
formed. They were national or international clinical data col-
lection or were based on the analysis of administrative data 
[26–31]. In both cases they showed different risks of adverse 
neonatal outcomes and different associations with specific 
antenatal maternal characteristics, this probably depending 
on the clinical features of the studied population. Obesity 
during pregnancy represents an important preventable risk 
factor for adverse pregnancy outcomes. It is associated with 
negative long-term health outcomes for both mothers and 
offspring [32]. These effects are often aggravated by the high 
incidence of abnormal glucose tolerance and excessive ges-
tational weight gain [33]. We found a significant impact of 
obesity in determining some neonatal outcomes.
Maternal obesity and gestational weight gain are asso-
ciated with childhood obesity, and this effect extends into 
adulthood. Childhood obesity in turn increases chances of 
later life obesity, type 2 diabetes, and cardiovascular disease 
in the offspring [34]. As compared to normal weight, mater-
nal obesity is associated with increased risks of gestational 
hypertension, preeclampsia, gestational diabetes, cesarean 
delivery, delivering large size for gestational age infants, and 
childhood obesity [35]. A sub-analysis of the HAPO study 
showed that both maternal GDM and obesity are indepen-
dently associated with adverse pregnancy outcomes. How-
ever, their combination has a greater impact than either one 
alone [36].
Another interesting study aimed to stratify the risk of 
neonatal outcomes using a classification and regression tree 
analysis. The authors found that high pre-pregnancy BMI 
was a predictor of LGA [37].
Importantly, the STRONG study confirmed that in a large 
Italian cohort obesity negatively impacts on maternal and 
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Pre-pregnancy BMI
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259
Pre-pregnancy BMI
>30 25-30
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452
76
255
Family history 
of diabetes
Yes No
Class 1
OR=1.68 (1.21-2.33)
Class 2
OR=1.38 (1.03-1.87)
Class 3
OR=1.17 (0.84-1.65)
Class 4
OR=1
Fig. 1  Identification of subgroups at different risks of developing the 
cumulative adverse neonatal outcome: results of the RECPAM analy-
sis. The REPCAM analysis identified subgroups of patients at differ-
ent risks of developing adverse neonatal outcome. The tree-growing 
algorithm modeled odds ratios (ORs) following a logistic regression 
with age, pre-pregnancy BMI, previous GDM, family history of dia-
betes, area of family origin, previous macrosomia, plasma glucose 
values at the beginning of pregnancy between 100 and 125  mg/dl 
(5.6–6.9  mmol/l) as global variables. Splitting variables are shown 
between branches, whereas a condition sending patients to the left or 
right sibling is on a relative branch. Class 4 with the lowest risk of 
developing adverse neonatal outcome was the reference category (OR 
1). Circles indicate subgroups of patients; squares indicate the patient 
subgroup REPCAM classes. Numbers inside circles and squares rep-
resent the number of events (top) and the number of nonevents (bot-
tom) respectively. An OR with the corresponding 95% CI (in paren-
theses) is shown for each class
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Table 3  Characteristics according to RECPAM classes
Class 1 Class 2 Class 3 Class 4 p
Age (years) 36.1 ± 4.9 36.4 ± 5.3 37.2 ± 5.0 36.7 ± 4.9 0.03
Age classes (%) 0.03
 ≤ 35 years 43.6 39.4 32.9 34.5
 > 35 years 56.4 60.6 67.1 65.5
Education (%)
 Low 38.4 31.8 22.2 20.8
 Median 48.0 48.5 48.9 48.3
 High 13.6 19.7 28.9 30.9
Occupation (%) 0.02
 Housewife 38.6 37.9 26.1 28.6
 Employed 59.7 61.4 73.3 70.8
 Student 1.7 0.8 0.6 0.6
Phisycal activity before pregnancy (%) 15.8 21.5 36.8 27.9 < 0.0001
Phisycal activity during pregnancy (%) 28.6 26.3 33.3 32.9 0.22
Alcohol before pregnancy (%) 4.4 6.2 9.9 7.4 0.12
Alcohol during pregnancy (%) 0.4 1.1 1.3 1.2 0.75
Smoke (%) 0.46
 No 74.5 79.4 78.3 78.9
 Yes 12.6 8.5 7.2 9.3
 Ex 13.0 12.1 14.5 11.8
Race Caucasian (%) 24.8 18.3 17.6 15.0 0.01
Family from areas of high diabetes preva-
lence (%)
12.0 11.4 8.6 6.4 0.03
Family history of diabetes (%) 44.0 42.9 100 0 < 0.0001
First pregnancy (%) 43.2 45.2 49.4 51.3 0.13
Number of previous pregnancy (n) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.04
Previous abortion (%) 23.3 29.4 28.2 24.3 0.21
Number of previous abortion (n) 1.0 (0.0–1.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–1.0) 0.05
Previous GDM (%) 18.9 17.5 16.5 13.1 0.15
Previous macrosomia (%) 7.7 5.3 2.4 2.2 0.001
Weight before pregnancy (kg) 92.1 ± 13.1 71.7 ± 6.9 59.1 ± 6.0 58.0 ± 6.7 < 0.0001
Height (cm) 162.9 ± 6.9 162.3 ± 6.7 164.5 ± 5.9 163.1 ± 6.4 0.0002
Pre-pregnancy BMI (kg/m2) 33.8 (31.2–36.7) 26.0–28.2 22.0 (20.5–23.4) 22.0 (20.3–23.4) < 0.0001
34.6 ± 4.1 27.2 ± 1.3 21.8 ± 1.9 21.8 ± 1.9
Pre-pregnancy BMI classes (%) < 0.0001
 < 25 kg/m2 0 0 100.0 100.0
 25–30 kg/m2 0 100 0 0
 > 30 kg/m2 100 0 0 0
Weight at OGTT (kg) 97.0 ± 13.5 78.4 ± 8.1 67.3 ± 8.2 66.0 ± 8.3 < 0.0001
Weight at end of pregnancy (kg) 98.9 ± 14.1 81.2 ± 8.5 70.6 ± 7.8 69.3 ± 8.4 < 0.0001
Weight gain (kg) 7.0 ± 6.1 9.5 ± 5.3 11.5 ± 4.9 11.3 ± 4.6 < 0.0001
Blood glucose at first trimester (mg/dl) 91.1 ± 11.0 90.0 ± 10.6 89.2 ± 11.2 85.8 ± 10.4 < 0.0001
First trimester blood glucose between 100 
and 125 mg/dl (%)
33.2 27.5 20.4 22.6 0.002
HbA1c at diagnosis % (mmol/mol) 5.5 ± 0.4 (35.4 ± 4.5) 5.4 ± 0.5 (34.9 ± 4.7) 5.4 ± 0.4 (34.3 ± 4.9) 5.2 ± 0.4 (33.3 ± 4.4) < 0.0001
16–18 weeks OGTT Blood glucose T0′ 
(mg/dl)
98.7 ± 8.9 97.1 ± 8.7 95.2 ± 8.6 89.3 ± 10.4 < 0.0001
16–18 weeks OGTT Blood glucose T60′ 
(mg/dl)
171.0 ± 36.0 158.8 ± 31.1 164.3 ± 35.2 165.6 ± 34.3 0.43
16–18 weeks OGTT Blood glucose T120′ 
(mg/dl)
136.2 ± 34.4 135.0 ± 33.7 129.9 ± 31.9 145.3 ± 38.8 0.36
 Acta Diabetologica
1 3
neonatal course during pregnancy. Therefore, great attention 
should be paid to obesity by clinicians.
As for malformations authors recently reported no evi-
dence for consistent association of GDM with birth defects, 
with the exception of a weak association between GDM and 
congenital heart defects. When stratified by maternal pre-
pregnancy BMI an association between GDM and congenital 
heart defects and between GDM and neural tube defects was 
evidenced only in women with both GDM and pre-preg-
nancy obesity [38].
When we looked at the characteristics of the subcat-
egories determined by the stratification model we noticed 
some interesting points. Women belonging to the highest 
risk group had the highest first trimester glucose values. 
This is in line with the results of the HAPO study [19, 
20] and was also documented by another study in which a 
regression tree analysis was performed [25]. In our study, 
we did not find a predictive role of first trimester blood 
glucose levels for none of the outcomes we have consid-
ered probably because all the studied women received a 
careful process of care, this reducing the risk of adverse 
outcomes. Women of the highest risk RECPAM class had 
also the highest blood pressure levels. This is a finding 
that should be investigated in the light of the well-known 
relationship between blood pressure disorders and adverse 
pregnancy outcomes. Women of the highest risk RECPAM 
class were more often Caucasian. Significant differences 
in perinatal outcomes exist across ethnicity in women with 
GDM. This finding emphasizes the need to better under-
stand ethnic-specific factors in GDM management and 
Table 3  (continued)
Class 1 Class 2 Class 3 Class 4 p
24–28 weeks OGTT Blood glucose T0′ 
(mg/dl)
93.8 ± 17.5 90.5 ± 16.4 88.8 ± 14.8 86.2 ± 16.0 < 0.0001
24–28 weeks OGTT Blood glucose T60′ 
(mg/dl)
175.2 ± 33.2 176.3 ± 29.2 179.2 ± 29.5 173.7 ± 30.0 0.35
24–28 weeks OGTT Blood glucose T120′ 
(mg/dl)
143.8 ± 32.9 148.7 ± 31.3 149.3 ± 28.0 145.8 ± 31.1 0.34
Systolic blood pressure (mmHg) 118.5 ± 14.7 112.6 ± 13.1 109.7 ± 12.4 109.7 ± 12.7 < 0.0001
Diastolic blood pressure (mmHg) 72.8 ± 10.0 70.9 ± 9.5 69.1 ± 8.7 68.4 ± 8.8 < 0.0001
Total cholesterol (mg/dl) 224.0 (187.0–254.0) 249.0 (210.0–269.0) 244.0 (217.0–268.5) 247.5 (211.0–277.0) 0.01
HDL cholesterol (mg/dl) 58.0 (49.0–74.0) 65.0 (55.0–79.0) 69.5 (62.5–79.5) 71.0 (62.0–83.0) 0.0003
LDL cholesterol (mg/dl) 128.4 (108.0–147.2) 138.5 (114.5–162.5) 141.5 (119.0–161.2) 144.0 (119.0–163.0) 0.07
Triglycerides (mg/dl) 171.0 (128.0–210.0) 186.0 (128.0–249.0) 146.0 (106.0–199.0) 154.0 (103.0–201.0) 0.02
Gestational week at first visit (weeks) 25.0 (19.0–28.0) 27.0 (23.0–30.0) 28.0 (24.0–30.0) 28.0 (26.0–30.0) < 0.0001
Ketones measurement (%) 52.5 51.9 51.8 51.0 0.98
Glucose lowering treatment (%) < 0.0001
 Diet 46.7 61.9 65.5 70.3
 Insulin 53.3 38.1 34.5 29.7
Insulin treatment started during the first 
visit (%)
13.3 18.8 13.0 12.1 0.35
Anti-ipertensive treatment (%) 10.8 4.0 1.6 1.8 < 0.0001
Antiplatelet treatment (%) 7.3 6.1 2.4 2.9 0.006
Levotiroxina treatment (%) 10.9 13.6 8.2 13.7 0.12
Other treatments (%) 22.2 15.5 16.9 17.1 0.19
Women attending the follow-up visit (%) 47.1 46.0 52.5 49.3 0.40
Follow-up OGTT T0′ (mg/dl) 94.4 ± 10.7 92.9 ± 11.5 89.3 ± 9.7 87.9 ± 8.8 < 0.0001
Follow-up OGTT T120′ (mg/dl) 109.4 ± 30.9 104.6 ± 26.7 100.4 ± 27.9 98.6 ± 27.4 0.003
Gestational week at delivery (weeks) 39.0 (38.0–40.0) 39.0 (38.0–40.0) 39.0 (38.0–40.0) 39.0 (38.0–40.0) 0.14
Gender of the newborn (%) 0.91
 Female 48.4 46.9 46.3 45.5
 Male 51.6 53.1 53.7 54.5
Number of glucose tests (n) 21.0 (14.0–28.0) 20.0 (14.0–28.0) 16.0 (12.0–28.0) 18.0 (14.0–28.0) 0.004
Weight at birth (g) 3315.9 ± 514.3 3267.3 ± 528.0 3214.8 ± 419.3 3232.8 ± 500.3 0.07
Lenght at birth (cm) 49.6 ± 2.7 50.4 ± 8.2 49.8 ± 2.2 49.8 ± 2.7 0.84
Composite outcome (%) 37.8 33.3 29.8 26.5 0.01
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the importance of developing strategies to address these 
disparities.
The other predictive factor of adverse neonatal outcomes 
we have found was previous macrosomia. In our study, it was 
associated with a high risk for several adverse outcomes as 
other studies have highlighted [39].
One of the main factor that could be linked to the devel-
opment of adverse outcomes is the glucose level of each 
OGTT points. A large retrospective study showed that OGTT 
measures were significantly associated with most adverse 
outcomes [40]. However, the magnitude and significance of 
risk for these outcomes differed by various combinations of 
abnormal glucose values [40].
When we tested the predictive role of the glucose levels 
of the OGTT points, we found no associations with neonatal 
outcomes. This finding was confirmed both in multivariate 
analyses and in RECPAM models.
We found six stillbirths, one neonatal death but no mater-
nal death in our study. These prevalence rates are in line with 
national rates reported by official regulatory Agencies.
Implications for clinical practice
The STRONG study allowed to recognize the need for a bet-
ter approach to care women with GDM. The risk stratifica-
tion based on the occurrence of adverse neonatal outcomes 
is a strategy focused on hard clinical parameters. The finding 
of a significant contribution of obesity and overweight in 
determining adverse outcomes requires particular attention 
to those conditions. Obesity is a status at increasing dif-
fusion and it is associated with several cardiovascular and 
metabolic diseases. Our study showed that it is one of the 
most important predictors of adverse neonatal outcomes. 
All women should be advised by health care professionals 
about the risks linked to obesity. A deep evaluation on risk 
factors leading to obesity or overweight is needed to prevent 
these conditions. Our study clearly demonstrates that some 
categories of women could need a more intensive care dur-
ing their pregnancy. On the other hand, some women could 
be considered low risk and they could need a less intensive 
clinical management and follow-up. This could change the 
management and follow-up of patients because low-risk 
women could have longer time between visits, lower num-
ber of obstetric visits, and ultrasounds compared to high-
risk women. The lack of OGTT prediction for none of the 
neonatal adverse outcomes has potential implications in the 
national setting. The two-step risk factor-based screening 
procedure for GDM now used in Italy could be not exactly 
well-performing in detecting high-risk pregnancies. The 
STRONG study could lead to a redefinition of national 
procedures for screening and diagnosis of GDM, based on 
the real risk of neonatal complications. Our study also has 
research implications. We used a regression tree analysis that 
is not common used. This could mean that a more detailed 
and sophisticated methodological approach is needed to 
catch more fine clinical aspects capable of determining high 
risk for the development of adverse outcomes.
Strengths and limitations
This is a large national multicenter study giving a national 
picture of the care and the outcome of pregnancies compli-
cated by GDM. Information on a great number of clinical 
parameters related to the pregnancy complicated by GDM 
and its follow-up was collected. Information on heath care 
resources needed for the care of GDM was also collected. 
This could allow to estimate the costs related to GDM care. 
Further sub-analyses could be performed on the basis of the 
collected data. One study limitation is not having planned 
a longer mother and children follow-up. We collected data 
until the women performed the first OGTT after pregnancy 
according to health care professionals advices.
Another important limitation of the study is the selec-
tion of women screened for GDM and therefore included in 
the study. The group of GDM included women who were 
detected earlier in pregnancy and women with GDM diag-
nosed at 24–28 weeks of pregnancy, so already providing a 
heterogeneous group with GDM, with some women receiv-
ing treatment earlier in pregnancy which might have affected 
outcome. However, we have performed a further analysis 
with the aim to test the effect of early diagnosis (i.e., at 
16–18 weeks of pregnancy) in determining adverse neonatal 
outcomes. We have performed a multivariate analysis with 
the same set of variables already tested in the multivariate 
analysis plus a new variable that was “diagnosis of GDM at 
16–18 weeks of pregnancy (yes or not)”. We have found that 
there was no statistically significant association between this 
variable and the occurrence of adverse neonatal outcomes 
(OR 1.44, 95% CI 0.54–3.86).
Moreover, being the screening based on risk factors this 
means that this is a selected group of women. Published data 
have showed that the application of the selective screen-
ing criteria would result in the execution of an oral glucose 
tolerance test in 58.3% of women and 23.0% cases of GDM 
would not be detected due to the absence of any risk factor 
[25].
Data could be, therefore, not applicable to a general GDM 
population detected by universal screening, but they are rep-
resentative of populations managed according to a selective 
screening strategy.
A deep investigation on the factors associated with 
adverse neonatal outcomes requires a risk stratification to 
identify subgroups of women at higher risk. This could lead 
to an improvement in the level of care with a cost reduction 
and a better resource allocation.
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